Basiliximab for the Treatment of Acute T‐Cell Mediated Rejection After Kidney Transplantation: Case Series and Preliminary Experience
Organ Medicine · 2025
DOI: 10.1002/orm2.70002 ↗At a glance
Journal article in Organ Medicine, 2025. Written by Tingting Chen and 8 co-authors. Cited 1 times so far (Crossref); 30 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Background
The study aims to evaluate the preliminary efficacy and safety of basiliximab in treating acute T cell‐mediated rejection (TCMR) after kidney transplantation, particularly in patients with poor responses to standard treatments.
Methods
We conducted a retrospective case series study involving eight kidney transplant recipients at Zhongshan Hospital, Fudan University, who received basiliximab for anti‐TCMR treatment. Baseline characteristics, immunosuppression management data, and treatment outcomes were collected.
Results
Among the eight patients, two had biopsy‐proven TCMR. Elevated serum soluble IL‐2R (sIL‐2R) level were detected in all patients before basiliximab treatment. Following basiliximab therapy, all patients exhibited a rapid decrease in sIL‐2R levels, and most cases showed a general downward trend in serum creatinine levels. Although two patients developed pulmonary infections posttreatment, no clear correlation was found between the use of basiliximab and infections. No other new infections or adverse reactions were reported.
Conclusions
Basiliximab therapy demonstrates efficacy and good tolerance in patients with TCMR.
Cite
APA
Chen, T., Liang, L., Chen, S., Xu, Q., Li, X., Xu, M., Rong, R., Zhu, T., & Yang, C. (2025). Basiliximab for the Treatment of Acute T‐Cell Mediated Rejection After Kidney Transplantation: Case Series and Preliminary Experience. Organ Medicine. https://doi.org/10.1002/orm2.70002
Vancouver
Chen T, Liang L, Chen S, Xu Q, Li X, Xu M, et al. Basiliximab for the Treatment of Acute T‐Cell Mediated Rejection After Kidney Transplantation: Case Series and Preliminary Experience. Organ Medicine. 2025. doi:10.1002/orm2.70002
BibTeX
@article{Chen2025,
author = {Chen, Tingting and Liang, Lifei and Chen, Siyue and Xu, Qing and Li, Xiaoyu and Xu, Ming and Rong, Ruiming and Zhu, Tongyu and Yang, Cheng},
title = {Basiliximab for the Treatment of Acute T‐Cell Mediated Rejection After Kidney Transplantation: Case Series and Preliminary Experience},
journal = {Organ Medicine},
year = {2025},
doi = {10.1002/orm2.70002}
}
EUVIMED